Equillium, Inc. (EQ)

NASDAQ: EQ · IEX Real-Time Price · USD
2.89
+0.07 (2.62%)
At close: Aug 15, 2022 12:41 PM
2.76
-0.13 (-4.63%)
After-hours: Aug 15, 2022 7:46 PM EDT
2.62%
Market Cap 99.19M
Revenue (ttm) n/a
Net Income (ttm) -67.48M
Shares Out 34.28M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,246
Open 2.81
Previous Close 2.82
Day's Range 2.81 - 2.91
52-Week Range 1.66 - 7.12
Beta 1.34
Analysts Buy
Price Target 13.43 (+364.1%)
Earnings Date Aug 8, 2022

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment o... [Read more...]

Industry Biotechnology
IPO Date Oct 11, 2018
CEO Bruce Steel
Employees 45
Stock Exchange NASDAQ
Ticker Symbol EQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for EQ stock is "Buy." The 12-month stock price forecast is 13.43, which is an increase of 364.06% from the latest price.

Price Target
$13.43
(364.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium to Present at Two Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #gvhd--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)

Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisi...

Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development U...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transpl...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Announces Appointment of Barbara Troupin to Board of Directors

LA JOLLA, Calif--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disord...

Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition

Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal, worth approximately $330 million, gives t...

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disor...

Equillium Provides Timing Update on Conference Presentations

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT ...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with hig...

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium To Reassess Potential For Its Asthma Trials

Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target peak and sustained reduction of CD6 at ...

Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the C...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Respons...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with hig...

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American C...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...